BioCentury | Nov 1, 2010
Company News

Predictive Biomarker Sciences Inc., Unibioscreen deal

...Predictive Biomarker will use its technology to characterize the mechanism of action of Unibioscreen's UNBS1450. The...
...tumor cell lines' response to drugs through the use of fluorescent reporters observed in real-time. Unibioscreen...
...for further development. Financial terms were not disclosed. Predictive Biomarker Sciences Inc. , Mesa, Ariz. Unibioscreen S.A....
BioCentury | Feb 26, 2009
Distillery Therapeutics

Indication: Cancer

...26, 2009 Patent application filed; available for licensing from Unibioscreen S.A. Contact: Unibioscreen S.A., Brussels, Belgium e-mail: business@unibioscreen.com...
BioCentury | Jan 12, 2009
Clinical News

UNBS1450: Phase I started

...a dose-escalation, European Phase I trial of intravenous UNBS1450 in patients with advanced solid tumors. Unibioscreen S.A....
BioCentury | Jan 5, 2009
Company News

Diatos, Drais deal

...also is developing UBNS 5162, a pan-antagonist of CXCL chemokines it licensed in September from Unibioscreen S.A....
BioCentury | Sep 22, 2008
Company News

Drais, Unibioscreen deal

...received exclusive, worldwide rights from Unibioscreen to develop and commercialize UNBS 5162 for all indications. Unibioscreen...
...in Phase I testing to treat advanced solid tumors. Drais Pharmaceuticals Inc. , Bridgewater, N.J. Unibioscreen S.A....
Items per page:
1 - 5 of 5
BioCentury | Nov 1, 2010
Company News

Predictive Biomarker Sciences Inc., Unibioscreen deal

...Predictive Biomarker will use its technology to characterize the mechanism of action of Unibioscreen's UNBS1450. The...
...tumor cell lines' response to drugs through the use of fluorescent reporters observed in real-time. Unibioscreen...
...for further development. Financial terms were not disclosed. Predictive Biomarker Sciences Inc. , Mesa, Ariz. Unibioscreen S.A....
BioCentury | Feb 26, 2009
Distillery Therapeutics

Indication: Cancer

...26, 2009 Patent application filed; available for licensing from Unibioscreen S.A. Contact: Unibioscreen S.A., Brussels, Belgium e-mail: business@unibioscreen.com...
BioCentury | Jan 12, 2009
Clinical News

UNBS1450: Phase I started

...a dose-escalation, European Phase I trial of intravenous UNBS1450 in patients with advanced solid tumors. Unibioscreen S.A....
BioCentury | Jan 5, 2009
Company News

Diatos, Drais deal

...also is developing UBNS 5162, a pan-antagonist of CXCL chemokines it licensed in September from Unibioscreen S.A....
BioCentury | Sep 22, 2008
Company News

Drais, Unibioscreen deal

...received exclusive, worldwide rights from Unibioscreen to develop and commercialize UNBS 5162 for all indications. Unibioscreen...
...in Phase I testing to treat advanced solid tumors. Drais Pharmaceuticals Inc. , Bridgewater, N.J. Unibioscreen S.A....
Items per page:
1 - 5 of 5